UPMC Hillman Cancer Center
Pittsburgh, PA
Jason Luke, M.D., is an Associate Professor of Medicine at the University of Pittsburgh and UPMC Hillman Cancer Center where he is Associate Director for Clinical Research and the Director of the Immunotherapy and Drug Development Center (Phase I). Dr. Luke specializes in early phase drug development for solid tumors and the management of melanoma. Dr. Luke is one of the foremost international investigators in immuno-oncology, having led clinical trials of immunotherapy modalities across novel checkpoints, bispecifics, innate immunity and oncolytic viruses and adoptive cell transfer for solid tumors. In melanoma, Dr. Luke designed and led two practice changing trials determining the role of anti-PD1 + CTLA4 after initial anti-PD1 failure (NCCN compendium listed) and altering the landscape of melanoma oncology practice across dermatology, surgery and medical oncology via establishment of modern adjuvant therapy with anti-PD1 for stage IIB/C disease (leading to FDA/EMA approval). Dr. Luke has been a major contributor toward the investigation of radiation and the microbiome in relation to cancer immunotherapy. Dr. Luke received his M.D. from Rosalind Franklin University of Medicine and Science in Chicago. He then pursued internship and residency in internal medicine at the Boston University Medical Center, medicine and medical oncology fellowships at Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center in New York City. Dr. Luke leads an R01 funded laboratory, he is co-PI for the Pittsburgh UM1 LAO and is project 3 clinical co-leader of the Pittsburgh Skin Cancer P50 SPORE, in addition to multiple private and state awards.
Disclosures:
Tuesday, October 1, 2024
2:32 PM – 2:44 PM ET